By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Urinary tract infections are common and unpleasant, but a research team at Vanderbilt University has developed a ...

An osteoanabolic agent should be the first choice treatment for patients at high or imminent risk for fracture, but once ...

The drug was also filed for approval in Europe in February, with a decision due in early 2023. Bad news for Biohaven There was disappointment for another ALS drug developer this week, however ...

Researchers at MD Anderson discussed the five possible approaches to treating graft-versus-host disease in a review article ...

The drug started a phase 2 trial in 2018, but, while it was still listed as an active programme in the company's July pipeline update, there has been no news for some time. Regeneron also said it ...

An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary ...

By a News Reporter-Staff News Editor at Health Policy and Law Daily-- A new study finds that CivicaScript, a not-for-profit drug manufacturer in the US, can reliably supply essential generic medicines ...

There is no generic version of this medication. It is typically a tier 3 medication in most drug plan formulary lists. Many Medicare Part D plans include Trulicity on formularies, but you’ll ...

Yutrepia's maker, Liquidia, has scheduled a first commercial shipment of the PH therapy to be available at specialty ...